Bausch Health Launches CABTREO in Canada

Bausch Health, Canada Inc. announced that its acne product, PrCABTREO™, is now covered by public drug plans in Quebec and Saskatchewan. This gel, combining clindamycin phosphate, adapalene, and benzoyl peroxide, is the first Health Canada-approved triple-combination topical treatment for acne. Intended for patients 12 years of age and older, CABTREO offers an innovative approach, combining an antibiotic, a retinoid, and an antibacterial agent to treat acne vulgaris.

CABTREO coverage already includes Ontario, Nova Scotia, and other programs, increasing accessibility for Canadians. Clinical studies show a 50% success rate with a 70% reduction in lesions. However, some mild or moderate reactions may occur.